Eli Lilly Reports Q3 Revenue of $24.4 Billion, Raises 2026 Guidance
Third-quarter revenue rose 39% to $24.4 billion, above analyst estimates of $22.58 billion. Adjusted EPS was $7.48 versus $5.68 expected. Lilly raised full-year revenue guidance to $91 billion-$92 billion from $85 billion-$87 billion and adjusted EPS guidance to $35-$36.
Story updates
Eli Lilly and Company announced its third-quarter 2026 financial results, reporting revenue of $24.4 billion, a 39% increase that surpassed analyst estimates of $22.58 billion. Adjusted earnings per share reached $7.48, significantly higher than the $5.68 expected by analysts. The growth was primarily fueled by the company's metabolic portfolio, with Mounjaro sales rising 65% to $10.72 billion and Zepbound sales increasing 49% to $5.35 billion. Following these results, the company raised its full-year revenue guidance to a range of $91 billion to $92 billion, up from its previous forecast of $85 billion to $87 billion.
Additionally, the company updated its adjusted earnings per share guidance to $35 to $36, reflecting adjustments for acquired in-process research-and-development charges.